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Introduction
 Benzodiazepines (BZDs) are widely available drugs. In the adult 
population, the prevalence of daily use of anxiolytic drugs is 4%, 
and the prevalence of daily use of hypnotics is 1.7%, according to a 
Spanish survey conducted in 2011 [1]. This is due to their anxiolytic, 
sedative, and hypnotic properties, and also because they have shown 
to have a broad-spectrum activity, a rapid onset of action, and a wide 
therapeutic window compared with other anxiolytic medications [2]. 
However, chronic use of BZDs has revealed that these drugs can lead 
to tolerance and dependence [3], as indicated by a BZD Withdrawal 
Syndrome (BWS) following cessation, characterized by nervousness, 
irritability, sleep disturbances, dizziness, tremor, diaphoresis and 
diarrhea, which can be complicated with seizures [4]. In addition, 
they associate a higher risk of impairments in cognition, memory, 
attention, reaction time and psychomotor function [5,6]. It has been 
estimated that 30 to 40% of long-term users of BZDs experience 
difficulties in withdrawing from these drugs [7]. The risk factors for 
BZD Dependence (BD) and BWS can be classified as those related 
with the drug properties (short half-life and high-power BZD), those 
related to the way how the BZD is used (use of high doses of BZDs, 
during more than 8 months and a rapid rate of taper) and those related 
to individual characteristics (previous history of drugs or alcohol 
dependence or abuse; history of a chronic disease; personality, 
anxiety or mood disorders; insomnia; females; elderly and a high 
cultural level) [2,8].
 Traditionally, the effective management of BZD discontinuation 
does not only include pharmacological management, but must 
address some of the nondrug issues that contribute to withdrawal 
severity and taper difficulty upon BZD discontinuation [3]. Because 
minimal interventions and systematic discontinuation programs 
guided by a physician or psychologist without the augmentation 
of psychotherapy or pharmacotherapy have demonstrated to be 
efficacious in a meta-analysis [9], it has been proposed a stepped care 
approach for discontinuing long-term BZD use. In addition, several 
adjunctive pharmacological agents have been used to facilitate the 
tapering of BZD. There is a consensus about gradual rather than 
abrupt tapering BZDs as a first step for BZD discontinuation 
[10,11]. Other extended traditional strategy has been switching from 
short half-life BZD to long half-life BZD before gradual taper, with 
different results as for support [12,13]. A great variety of agents have 
been used as adjuvant medication in BWS with varying degrees of 
success. Such agents include antidepressants such as mirtazapine [14], 
paroxetine [15], trazodone [16,17], dothiepin [18] and imipramine 
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 Chronic use of Benzodiazepines (BZDs) can lead to tolerance 
and dependence, as indicated by a BZD Withdrawal Syndrome 
(BWS). In general, it is preferred a gradual than an abrupt tapering 
of BZDs as a first step in the treatment of BZD Dependence (BD). 
In addition, a great variety of agents have been used as adjuvant 
medication for BD. Recently, research has focused in the use of 
Anticonvulsant (AC) drugs. The aim of this article is to review the use 
of AC in the management of BWS and BD.
Methods
 MEDLINE and the Cochrane were searched, selecting studies 
from 1980 until 2014, in which a pharmacological intervention with 
classic and new AC was made for discontinuing long-term BZD use.
Results
 In regard to classic AC, there were identified 10 studies related 
to carbamazepine and 4 studies related to valproate. On one hand, 
whereas there is a great body of research involving carbamazepine 
and there is a consensus about its efficacy for discontinuing 
long-term BZD use, especially in terms of improving drug-free 
outcomes, there have been brought inconclusive results in regard to 
valproate. On the other hand, studies identified of the new AC are 
as follows: 2 for gabapentin, 2 for oxcarbazepine, 2 for pregabalin, 
1 for tigabine and 2 for topiramate. With the exception of pregabalin, 
only small studies and cases report have been conducted for most 
of the new AC. Pregabalin has demonstrated to be effective in the 
treatment of BD and BWS, exerting its beneficial action by reducing 
the severity of withdrawal and anxiety symptoms.
Conclusion
 To date, among AC agents, only carbamazepine and pregabalin 
can be considered as augmentation alternatives for the treatment 
of long-term BZD use. Further randomized, double-blind, 
placebo-controlled studies are necessary to increase the knowledge 
to support the use of AC for the treatment of BD and BWS.
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[19,20]; β-blocker propranolol [21,22]; α2-agonist clonidine [23]; 
5-HT1A partial agonist buspirone [19,20,24]; anxiolytic alpidem [25]; 
neuroactive steroid progesterone [26]; 5-HT3 antagonist odansetrone 
[27]; and BZD partial agonist flumazenil [28,29].
 Moreover, in the past few years, research has focused in the use 
of Anticonvulsant (AC) drugs. Classic AC, such as Carbamazepine 
(CBZ) and Valproate (VPA), especially CBZ, have been widely studied 
for the treatment of BD and BWS [17,30]. However, because of their 
drug-to-drug interactions, the need of careful monitoring of serum 
drug levels, and hepatic and hematologic toxicity, their use is limited 
[31]. New AC agents offer several advantages over classic AC: they 
have rapid onset of action, lower toxicity, fewer side effects, and 
lower interaction with alcohol and other drugs [32]. AC offer several 
potential advantages in the BZD detoxification process: 1) they 
decrease the probability of experiencing a seizure, which is a severe 
complication of BWS [33]; 2) they are efficacious in blocking the 
“kindling” effect, which refers to the neural sensitization leading to 
progressive worsening of subsequent withdrawal episodes [34]; 3) 
they lack abuse liability [35]; 4) they are useful in treating anxiety 
and affective symptoms that can be evident during protracted BWS 
[36]; and 5) they lack cognitive and psychomotor impairing effects 
[37]. The aim of this article is to review the use of AC agents in the 
management of BWS and BD.
Methods
 MEDLINE and the Cochrane were searched, selecting studies 
from 1980 until 2014, in which a pharmacological intervention with 
classic and new AC was made for discontinuing long-term BZD use 
in both, mono-dependence cases or associated to other Substance 
Use Disorder (SUD). Major search terms included anticonvulsants, 
carbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbaze-
pine, pregabalin, tiagabine, topiramate, valproate, vigabatrine and 
zonisamide, on one hand, and BD, BWS and BZD-discontinuation, 
on the other hand. References of identified citations were searched 
manually to identify papers not located in the in the electronic 
database search. We independently evaluated each citation for 
inclusion. All clinical studies, regardless of their design were reviewed.
Results
Classic anticonvulsants
Carbamazepine: There is a great body of research involving CBZ. 
The first study of the successful use of CBZ in BWS was a case series 
of 3 patients who were treated with Alprazolam (ALP) at dosages 
higher than 5 mg/day because they suffered from Panic Disorder 
(PD). CBZ, given in a dosage that ranged from 600 to 800 mg/day for 
2 weeks, resulted in a successful reduction of withdrawal symptoms 
[38]. In a further case series of 9 patients who were taking high doses 
of BZDs [Chlordiazepoxide (CHL) 2000 mg/day, Clonazepam (CZP) 
8 mg/day and ALP 15 mg/day] and who also met criteria for a 
diagnosis of another SUD, CBZ provided a better tolerated and more 
rapid discontinuation from BZDs than a taper alone [39]. These initial 
positive results found in the use of CBZ in the treatment of BWS led to 
the development of a standardized protocol by Ries [40]. Eighty-five 
patients, who had BZDs as the primary drugs of abuse, were included 
in the study. Two slightly different protocols were developed: in the 
first protocol, a 3-day tapering dose of BZDs was given along with a 
loading dose of 600 mg/day of CBZ; in the second, CBZ was given in 
an initial loading dose, although there was no regularly schedule for 
BZD discontinuation. Both protocols were rated by the medical staff 
as better than previous methods of detoxification.
 Furthermore, open-label and randomized, double-blinded, 
placebo-controlled trials have been also published. The first 
double-blind, placebo-controlled trial was carried out by Rickels 
et al., in 1990 [41]. Initially, patients who were on BZDs other than 
Diazepam (DZP), Lorazepam (LZM), or ALP were shifted to a DZP 
equivalent dosage. Afterwards, patients were pretreated with CBZ 
(200-600 mg/day (n=13) or Placebo (PLA) (n=45), for 2 weeks. For 
the final 2 weeks, CBZ, still under double-blind conditions, was 
replaced by PLA. Three and 12-months follow-ups were also 
conducted. CBZ was associated with a significantly higher percentage 
of patients that remained BZD-free for at least 5 weeks when 
compared to PLA (91% vs. 58%, p<0.05). These findings were 
replicated in an open-label study, which included 18 patients 
(15 females and 3 males) with a BD [the mean duration of their 
dependency was 9.05 years and the most frequent BZD used was 
DZP, followed by LZM and Bromazepam (BRO)], 9 of whom were 
gradually tapered from BZDs, while the remaining 9 were additionally 
treated with CBZ (300-600 mg/day) for a further 15 days after BZD 
discontinuation. Withdrawal, anxiety and depressive symptoms were 
assessed every 3 days during the study period. This study found that 
there was a clear trend towards less severe withdrawal symptoms in 
the CBZ group, reaching significance on days 9-12 after withdrawal. 
Withdrawal symptoms such as hypersensitivity to sensory stimuli, 
abnormal perception of movement, depersonalization or 
derealisation were also less severe in the group treated with CBZ 
[42]. Concurrently, Schweizer et al., [30] conducted a 12-week, 
randomized, double-blind, placebo-controlled trial, in which 
40 long-term BZD users (21 females and 19 males, with a mean age 
of 47 years) were randomly assigned to receive treatment with CBZ 
(200-800 mg/day) or PLA for 10 weeks, together with a BZD tapering 
of 25% per week during 4 weeks. The mean duration of the BZD use 
was 64 months, and the most frequent BZDs used were ALP, LZM 
and DZP. There were significant differences in the patient’s ability 
to stay off BZDs in favor of the CBZ group at week 5 compared to 
the PLA group (95% vs. 62%, p<0.03), although only trend-level 
differences were observed between both treatment groups at week 12 
(74% vs. 52%, p=N.S.). In addition, patients receiving CBZ reported 
a larger reduction in withdrawal severity than patients receiving 
PLA, but only at a trend level, and only on the daily patient-rated 
withdrawal checklist. Eleven patients (28%) required antidepressant 
therapy for depression or panic when assessed at 12-weeks follow-up. 
CBZ resulted an effective adjunctive therapy for BWS, particularly in 
patients receiving BZDs in daily dosages of 20 mg/d or greater of DZP 
equivalents [30]. Finally, Klein et al., [43] examined the possibility 
that patients with PD are especially vulnerable to ALP withdrawal. 
After a 2-month open trial of ALP, 36 patients with PD and 35 patients 
with Generalized Anxiety Disorder (GAD) entered a controlled 
discontinuation phase, in which CBZ or PLA was added in a 
randomized, double-blind, placebo-controlled fashion, followed 
after 1 week by a single-blinded dose reduction of ALP, approximately 
25% every third day. 52% of the patients were able to discontinue ALP, 
but only 37% completed the study, maintaining ALP-free status for 4 
weeks. Patients with PD encountered more withdrawal problems than 
patients with GAD and seemed to benefit more from the addition of 
CBZ [43].
 Only one study has evaluated CBZ (400 mg twice a day) for the 
treatment of BZD abrupt discontinuation, in 17 patients who had 
a BD for more than 0.5 years because of PD or neurosis. Although 
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perception disturbances were noted in 14 patients and most patients 
showed sleep disturbances, mood alterations or anxiety, epileptic 
seizures did not occur. CBZ treatment was well tolerated by all 
patients and caused no severe problems [44].
 CBZ has also been used in the treatment of geriatric population. In 
a case series, it was reported that 4 hospitalized elderly patients (with 
a mean age of 72.5 years) who suffered from an ALP dependence were 
successfully withdrawn with CBZ, which was titrated up to 400-500 
mg/day, at the same time that BZD taper occurred over a period of 
2-6 days. All the patients were able to reduce their ALP use to no 
more than 2.5 mg/day and they experienced only mild withdrawal 
symptoms [45]. Subsequently, a double-blind study was performed 
to evaluate CBZ for the treatment of BWS in elderly patients. 36 
outpatients aged 60 years or over, suffering from GAD and BZD 
abuse, underwent gradual discontinuation of BZD therapy in two 
groups, one treated with CBZ and one with PLA. The CBZ-treated 
group demonstrated a lower incidence of withdrawal (p<0.01) and 
anxiety (p<0.05) symptoms [46].
 To conclude, a recent Cochrane systematic review points to the 
potential value of CBZ as an effective intervention for BZD gradual 
taper discontinuation, particularly in patients receiving BZDs at 20 
mg/day or more DZP-equivalent dosages. CBZ showed rather modest 
benefit in reducing withdrawal severity, although it did significantly 
improve drug-free outcome [47].
Valproate: Less has been published about the use of VPA in the 
treatment of BD and BWS. Three cases reported have found VPA 
to be effective in the treatment of BD and BWS. The first to report 
on the use of VPA in BD was Roy-Byrne. It was the case of a 
44-year old man diagnosed with Bipolar Disorder and who had 
been on ALP (2-5 mg/day) for over 3 years. Two initial attempts to 
discontinue BZDs, one tapering ALP and the other switching to 
CZP and tapering CZP had been unsuccessful, reporting the patient 
increased depression, tremulousness and mood swings. In the third 
attempt of ALP discontinuation, VPA was used, being found to 
be efficacious in discontinuing BZDs and maintaining the patient 
BZD-free 6 months after VPA was initiated [48]. Apelt and Emrich 
[49], a short time later, published a case series of 4 inpatients (aged 
24-44 years) diagnosed with BD (BZD use ranged from 1 to 18 
years), in which symptoms of protracted BZD withdrawal, including 
psychosis, anxiety, panic, vomiting, insomnia, ataxia, and paresthesia 
that appeared between 11 and 21 days after BZD tapering, were 
successfully treated with VPA [49]. Finally, McElroy et al., [50] 
reported the case of a 23-year-old male with a severe treatment-re-
sistant PD complicated by CZP-induced interdose rebound and 
withdrawal symptoms. The patient had initially been treated with 
DZP (90 mg/day), but an attempted taper of DZP resulted in an abrupt 
increase of daily panic and generalized anxiety (55 mg/day). CZP 
was substituted over a 3-day period with a final dose of 12 mg/day 
over four doses. However, the patient continued to complain of 
generalized anxiety and he experienced a worsening of symptoms 
when CZP was attempted to be reduced. For this reason VPA was 
added and increased to a total dose of 2250 mg/day. CZP was 
then discontinued without anxiety or withdrawal symptoms [50]. 
However, in the only randomized, double-blind, placebo-controlled 
study, in which 78 patients, taking a mean dose of 19 mg/day of DZP 
(or its equivalent), were stabilized for several weeks on their BZD 
(16 DZP, 25 LZM and 37 ALP) and then pretreated for 1-2 weeks 
with Trazodone (TRA) (100-500 mg/day) (n=41), VPA (500-2500 
mg/day) (n=19) or PLA (n=18), before being tapered at 25% per week, 
failed to find any significant effect on withdrawal severity, although 
more patients remained BZD-free in the VPA group compared to 
patients in the TRA and PLA groups (79% vs. 67% vs. 31%, 
respectively, p<0.03) at week 5. Taper success did not remain 
significant at 12-week follow-up. Major adverse events for VPA were 
diarrhea, nausea and headache [17].
New anticonvulsants
Gabapentin: Gabapentin (GBP), 1-(aminomethyl) cyclohexaneacetic 
acid, is a second generation anticonvulsant, which has shown to bind 
with high affinity to α2δ1-subunit of voltage-gated calcium channels 
[51]. Through this mechanism, GBP can cause a decrease in calcium 
influx in presynaptic nerve terminals and inhibit the release of 
excitatory aminoacids such as Glutamate (GLU) [52], Noradrenaline 
(NA), Dopamine (DA) and Serotonin (5-HT) [53]. GBP lacks 
drug-to-drug interactions due to absence of protein binding and 
hepatic metabolism, so it is not affected by liver dysfunction. In 
addition, it has a renal excretion as an unchanged drug. It also lacks 
cognitive impairment and lacks abuse potential, not requiring blood 
monitoring [54].
 To date, only one case report [55] and an open-label study [56] 
have been published in regard to the use of GBP in the treatment of 
BD. Crockford et al., were the first to report the case of a 49 year-old 
woman, with a 7-year history of continuous intake of 12 to 15 mg 
of ALP per day, who was successfully detoxified using GBP (600 
mg/day), after having failed a tapering approach with CZP 2 mg twice 
daily. She reported a rapid reduction of symptoms of anxiety, tremor 
and affective lability, and 2 months later she remained ALP-free 
[55]. At the same time, a Spanish group communicated in a Spanish 
Congress the results of a 3-month, open-label, prospective study 
which included 17 patients (53% females and 47% males), who 
were under an Opiate Substitution Treatment with Methadone and 
met DSM-IV criteria for BZD abuse or dependence. GBP was given 
in a range of dosage from 1200 to 4800 mg/day (mean dosage 2588 
mg/day) and BZDs were gradually tapered for 21 days. The 60% of the 
patients remained BZD-free at the end of the study. In addition, there 
was a reduction in withdrawal and anxiety symptoms, as well as in 
perceived stress, with an improvement in global functioning. GBP was 
well tolerated in general, with mild and transient side effects such as 
dizziness and dry mouth, which progressively disappeared [56].
Oxcarbazepine: Oxcarbazepine (OXC), the 10-keto-analogue of 
CBZ, is a new generation anticonvulsant whose mechanism of action 
is thought to be by a double pathway: 1) blocking voltage-sensitive 
sodium channels, thereby stabilizing neural membranes, inhibiting 
repetitive neuronal firing, and reducing synaptic impulse activity; 
and 2) reducing high voltage-activated calcium currents in striatal 
and cortical neurons, thus reducing glutamatergic transmission 
at corticostriatal synapses [57]. In contrast to CBZ, OXC’s major 
route of elimination is through renal excretion and not through the 
cytochrome P450 oxidase system, which implies an enhanced 
tolerability, lower drug-interaction potential and reduced liver 
toxicity than CBZ. Its steady-state is reached within 2-3 days (half-life 
8-10 hours) which is even earlier than CBZ.
 Until now, only a German group has published two case series 
studies of OXC for BZD detoxification. In the first study they reported 
the cases of 3 patients (one male and one with comorbid alcohol 
dependence) [58]. In the later study, 10 patients (2 males and 
8 females) who fulfilled DSM-IV and ICD-10 criteria of BD, and who 
were taking BZDs in an equivalence-dose of DZP of 20-300 mg/day, 
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Duration; Intervention Outcomes Results
CARBAMAZEPINE
Klein et al., N=3 CS 2 weeks ALP withdrawal (>5 mg/d) CBZ (600-800 mg/d) Reduction of withdrawal symptoms
CBZ was associated with a successful 
reduction of withdrawal symptoms
Ries et al., N=9 CS BD (CHL 2000 mg/d, CZP 8 mg/d and ALP 15 mg/d) + PSUD CZP + BZD tapering Discontinuation of BZD intake
Discontinuation of BZD was well tolerat-
ed and rapid
Rickels et al., N=58
DB, PC trial 2-4 weeks BZD stabilization period 
+ 2 weeks of treatment period + 2 weeks of PLA 
treatment + 12-months follow-up CBZ (200-600 mg/d) 
(n=13) vs PLA (n=45)
Ability of the patients to remain BZD free for 
at least 5 weeks
CBZ caused a significantly higher % 
of patients who remained BZD-free com-
pared to PLA (p<0.05)
Ries et al., N=85
2 treatment protocols: 3 days
Protocol 1: CBZ (600 mg/d) + BZD tapering Protocol 
2: CBZ (600 mg/d) without BZD tapering
Staff ratings compared to previous detoxifica-
tion methods
CBZ was rated as better than previous 
detoxification methods
García-Borreguero et al., 
N=18
R, C study 15 days BD (mean duration 9.05 years. 
DZP, LZM and BRO the most frequently BZD used) 
Gradual BZD tapering (n=9) vs adding CBZ (300-600 
mg/d) (n=9)
Withdrawal (BWSQ-2), anxiety (SAS) and 
depressive (SDS) symptoms
CBZ was associated with a trend 
towards lesser severe withdrawal 
symptoms
Swantek et al., N=4
CS 2-6 days
Elderly patients ALP dependence 
CBZ (400-500 mg/d) + BZD tapering
Reduction of ALP use
Intensity of withdrawal symptoms
All patients were able to reduce the 
dose of ALP used (no more than 2.5 
mg/d)
Patients experienced only mild with-
drawal symptoms 
Schweizer et al., N=40
R, DB, PC ALP, LZM or DZP dependence
CBZ (200-800 mg/d) + BZD tapering 25% per week Achievement of BZD-free Intensity of with-drawal symptoms
More patients in the CBZ group 
remained BZD-free and there was a 
greater reduction in withdrawal severity 
in this group
Di Constanzo et al., N=36
DB, PC Elderly patients with GAD + BZD abuse 
CBZ + Gradual BZD tapering Withdrawal (PWCL, HSCL) and anxiety (HARS) symptoms
CBZ-treated group demonstrated a 
lower incidence of withdrawal (p < 0.01) 
and anxiety (p < 0.05) symptoms
Klein et al., N=71
2-month OL of ALP + Discontinuation phase R, DB, 
PC + 1-week SB dose reduction of ALP
PD (n=36) and GAD (n=35) 
ALP discontinuation
CBZ vs PLA with BZD tapering 25% each 3 days
Achievement of BZD-free Withdrawal 
symptoms
52% of the patients were able to discon-
tinue ALP, but only 37% completed the 
study, maintaining ALP-free status for 4 
weeks. Patients with PD encountered 
more withdrawal problems than patients 
with GAD and seemed to benefit more 
from the addition of CBZ
Kaendler et al., N=17 OL BZD use for at least 0.5 years Abrupt withdrawal + CBZ (400 mg twice a day)
Anxiety, mood alterations, perception 
disturbances, neurological symptoms and 
vegetative signs
Perception disturbances were noted in 
14 patients. Most patients showed sleep 
disturbances, mood alterations and 
anxiety. However, epileptic seizures did 
not occur
VALPROATE
Roy-Byrne et al., N=1 CR BD + ALP dependence (2-5 mg/d) VPA + BZD tapering
Achievement of BZD free Withdrawal 
symptoms
VPA was efficacious in discontinuing 
BZDs and maintaining the patient BZD-
free after 6 months
Apelt et al., N=4
CS BRO, DZP, LZM and CHL dependence
VPA (1200 mg/d) Efficacy in treating Protracted BZD Withdraw-al Symptoms
Protracted BZD Withdrawal Symptoms 
ended when VAL was initiated
Mc Elroy et al., N=1
CR
CZP withdrawal
VPA (up to 2250 mg/d) + CZP tapering
Succeed in CZP discontinuation without 
withdrawal symptoms
CZP was discontinued without withdraw-
al and anxiety symptoms
Rickels et al., N=78
R, DB, PC 12 weeks BD (mean dose of 19 mg/d DZP 
or its equivalent; BZD used: 16 DZP, 25 LZM and 37 
ALP) VPA (n=19) (500-2500 mg/d) vs TRA (100-500 
mg/d) (n=41) vs PLA (n=18) + BZD tapering 25% 
per week
Peak severity during taper (PWCL) BZD 
status 5-weeks post-taper defined as off od 
on BZD
Peak PWCL change from baseline to 
peak severity was 16.4 for TRA, 18.04 
for and 18.24 placebo (F = 0.10; NS). 
More patients remained BZD-free in the 
VPA group compared to patients in the 
TRA and PLA groups (79% vs 67% vs 
31%, respectively, p<0.03) at week 5.
Table 1: Studies in which classic AC have been assessed for the discontinuation of long-term BZD-use.
ALP: Alprazolam; BD: Benzodiazepine Dependence; BRO: Bromazepam; BWS: Benzodiazepine Withdrawal Syndrome; BWSQ-2: Benzodiazepine Withdrawal Symp-
tom Questionnaire; BZD: Benzodiazepine; C: Controlled; CBZ: Carbamazepine; CHL: Chlordiazepoxide; CS: Case Series; CZP: Clonazepam; DB: Double-Blind; DZP: 
Diazepam; GAD: Generalized Anxiety Disorder; HSCL: Hopkins Symptom Check List; LZM: Lorazepam; OL: Open-Label; PC: Placebo-Controlled; PD: Panic Disorder; 
PLA: Placebo; PWCL: Physician Withdrawal Check List; R: Randomized; SAS: Self-Rating Anxiety Scale; SB: Single-Blind; SDS: Self-Rating Depression Scale; TRA: 
Trazodone; VPA: Valproate
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for at least 4 weeks, were included. The entire inpatient withdrawal 
lasted 11 to 21 days and OXC was maintained for a further 6-month 
period [59]. In both studies, DZP equivalence-dose taken before 
admission was calculated in each case and all patients were then 
withdrawn from DZP, so that for Low-dose-dependence (up to 
30 mg/day) DZP was reduced by 5 mg every 2 days, whereas for 
High-dose-dependence (more than 30 mg/day) DZP was reduced 
by 25% every 2 days to approximately 30 mg/day, after which they 
proceeded as with Low-dose-dependence. At the same time, OXC was 
titrated following the next scheme: 150 mg/day for the first 4 days; 
150 mg every two days up to a dosage of 1200 mg/day, from day 5 to 
day 12. It was found that all patients detoxified with OXC completed 
the withdrawal successfully without withdrawal symptoms, remaining 
abstinent from BZD after discharge. In addition, OXC was well 
tolerated.
Pregabalin: Pregabalin (PGN), (S)-3-(aminomethyl)-5-methyl-
hexanoic acid, is an antiepileptic drug of the third generation, and 
a structural analog of GABA acid, which binds selectively the α2δ 
subunit of voltage-gated calcium channels and reduces the influx of 
calcium, subsequently reducing the exocytosis of synaptic vesicles 
in the synaptic site [60], as a result of which it acts as a presynaptic 
modulator of the excessive release in hyperexcited neurons of 
excitatory neurotransmitters including GLU, NA and substance 
P [61]. PGN’s pharmacokinetic profile is linear with rapid oral 
absorption and a bioavailability of at least 90%. Peak plasma 
concentrations occur between 0.7 and 1.3 hours. It has no potential 
binding to plasma proteins. It lacks of metabolites. Its elimination 
half-life is 6 hours and steady-state is achieved within 24-48 hours, 
being renal excretion essentially the only pathway for its systemic 
elimination. In view of dose-dependent adverse reactions and since PGN 
is eliminated primarily by renal excretion, daily dose of PGN should be 
adjusted based on renal function. PGN does not inhibit the major 
cytochrome P450 enzymes and therefore it shows no drug-to-drug 
interaction [62].
 To date, the greater body of research in the treatment of BD and 
BWS involves PGN. The first group to report on the effectiveness of 
PGN for treating BWS was Biermann et al., [63]. They reported a 
case of a 39 year-old patient diagnosed with Social Phobia (SP) and 
GAD, who was also suffering from a depressive episode with sleep 
disturbances and BD (he had been using ALP 5 mg die for 4 years). 
PGN (up to 300 mg/day) was given with the aim of treating social 
and generalized anxiety, as well as lessening symptoms of BZD 
withdrawal. ALP was switched to DZP, which was tapered until 
cessation. However, 12 days after terminating DZP treatment the 
patient reported undesirable side effects due to PGN (facial 
hypoesthesia and tongue swelling), which motivated the 
discontinuation of PGN treatment. This resulted in a re-emergence of 
symptoms such as generalized anxiety, sleep dysfunction, agitation, 
tremor, headache, paresthesia concerning temperature, freezing and 
mild shivering, muscle pain, gastrointestinal irritations and mood 
instability, which were attributed as BZD withdrawal symptoms, 
concluding the authors that PGN could be useful for treating BZD 
withdrawal.
 Subsequently, a Greek group [37,64-67] reported a small series of 
four female patients with a long history of uninterrupted high-dosage 
BD (ranging from 5 to 27 years), who were incrementally switched to 
PGN at doses that ranged from 225 to 600 mg/day (mean dosage 390 
mg/day) within 3-7 weeks (mean duration of substitution process 5 
weeks). In this case, PGN was found to be effective in terms of reducing 
anxiety levels by 60-80% [64]. These encouraging findings motivated 
the same group to carry out an open-label clinical study in which 15 
patients (12 females and 3 males) with chronic BD (mean duration of 
BZD use of 13.23 years) and a concomitant affective disorder, mainly 
major depressive disorder or dysthymic disorder, were switched from 
their previous BZD to PGN in a dosage that ranged from 225 to 900 
mg/day (mean dosage 465 mg/day) in a substitution process that 
lasted from 2 to 14 weeks (mean duration 5.53 weeks). On 
completion of the transition process, anxiety and depressive levels 
dropped by 53.2% and 51.5%, respectively. PGN’s side effects were 
transient and included dizziness, fatigue, sedation, leg cramps and 
dysarthria [65]. In the most recent study designed by this group, 
they went a step forward, exploring the effects of PGN in the 
neurocognitive performance of 14 female patients with long-term 
BZD use (the mean duration of the BD was 15.43 years, range 3-30 
years), who had a comorbid diagnosis of a dysthymic disorder and/or 
a personality disorder of the Cluster B [37]. The BZDs taken by 
these patients were as follows: BRO at 9 mg/d (5 patients), ALP at 
1-6 mg/day (6 patients) and LZM at 4-7 mg (3 patients). PGN was 
incrementally substituted for BZD in a dosage that ranged from 150 
to 900 mg/day (mean dosage 509 mg/day), lasting the substitution 
process 3.5 weeks (range from 3 to 7 weeks). Patients improved 
substantially in overall cognitive functioning from baseline to 
2-month follow-up after the completion of the transition from BZD 
to PGN (p=0.017). This improvement was attributable mainly to 
their improvement in orientation (p<0.03), especially orientation 
in time (p<0.03), and to a much lesser extent to an improvement in 
memory recall (p=N.S.). In addition, they improved in measures of 
psychomotor speed (p=0.041), visuospatial memory (p=0.02) and 
learning (p=0.011), although they failed to improve in tests of 
attentional flexibility (p=N.S.). The authors concluded that the 
possible adverse cognitive effects of PGN-use in the treatment of 
long-term BD are less severe than those of prolonged long-term BZD 
use.
 Concurrently, a Spanish group has also carried out a multicenter, 
12-week, prospective, uncontrolled and observational study, which 
included 282 patients diagnosed with BD regardless of if they met 
criteria for other SUD. The most frequent BZD abused was ALP 
(n=177, 62.8%), the mean duration of the BD was 2 years, and the 
average number of previous detoxification attempts was 0.7. PGN 
was titrated from day 1 with a starting dose of 75 mg, which was 
up-titrated at 75 mg intervals on a weekly basis to 300 mg after 4 
weeks. At the same time, BZDs were tapered by 25% at weekly intervals 
until completely withdrawn after 4 weeks. PGN´s mean dose was 
315 mg/day (ranging from 25 to 450 mg/day). It was found that the 
success global rate defined as the achievement of a BZD-free status 
at week 12 was 52% (58% for women and 46% for men) (p=0.0516), 
although it increased up to 70% when only patients who completed 
the 12-week follow-up (n=211) were considered. The proportion of 
patients who were BZD-free at the end of the study did not differ 
according to the BZD abused or the presence of other SUD. In 
addition, significant and clinically relevant improvements in 
withdrawal (p<0.0001) and anxiety (p<0.0001) symptoms, as well 
as patient’s global functioning were observed associated to PGN 
treatment. The authors concluded that because the improvement in 
anxiety symptoms in the study, especially the physic symptoms, was 
clinically relevant as early as the first week, this rapid onset of the 
anxiolytic effect of PGN may play an essential role in the subsequent 
success of BZD withdrawal [36,68]. In a secondary analysis of this 
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study, the authors found that PGN was also effective in improving 
subjective sleep quality in this population group, measured with 
the Medical Outcomes Study Sleep Scale (MOS Sleep Scale). Its 
mean score was reduced by 55% at the end of the study (p<0.001), 
reaching clinical relevancy as early as from week 2. The effect of PGN 
on overall sleep problems was similar regardless of the BZD abused. 
The authors concluded that the mechanism that could be underlying 
the improvement in sleep measures associated to PGN could be 
related to its efficacy in improving anxiety symptoms [69]. PGN’s 
tolerability was considered excellent or good in most subjects.
 Finally, the results previously described above have been 
confirmed in a recent 12-week, double-blind, placebo-controlled trial 
which included 106 outpatients with a lifetime diagnose of GAD 
who had been treated with BZD for 8-52 weeks. Patients were first 
stabilized for 2-4 weeks with ALP in the range of 1-4 mg/day and 
then randomized to treatment with either PGN (300-600 mg/day) or 
PLA while undergoing a gradual BZD taper at a rate of 25% per week, 
followed by a 6 week BZD-free phase during which they continued 
double-blind study treatment. Although the proportion of patients 
who remained BZD-free was higher in the group taking PGN than 
PLA (51.4% vs. 37.0%, respectively) this difference did not reach 
statistical significance. However, among the subgroup of study 
completers, 95.5% of patients receiving PGN were relapse-free at the 
end of the study, compared with 80% receiving PLA. In addition, 
treatment with PGN was associated with a significant reduction in 
anxiety (p<0.001) and withdrawal (p=0.012) symptoms, with an 
improvement in cognitive and psychomotor profile. PGN was well 
tolerated, and the only two adverse events reported were dizziness and 
paresthesias [70].
Tiagabine: Tiagabine (TGB) is a selective GABA Transporter 1 
(GAT1) reuptake inhibitor, which has anxiolytic properties through 
the facilitation of GABAergic neurotransmission [71,72] and also acts 
through an indirect GABAergic inhibition on the DA-driven reward 
system of the brain [73], mechanisms which could contribute to its 
efficacy in the treatment of BD.
 To date, only one case report has been published in regard to the 
use of TGB in the discontinuation of long-term BZD use. It was the 
case of a 68-year-old female with a 15-year history of GAD and BD. 
For the last 5 years she was abusing BZDs, taking BRO at a dosage 
of 75 mg/day. TGB was incrementally substituted up to 15 mg/day 
for BRO within one week, each day replacing 10 mg of BRO with 
2 mg of TGB. TGB was found to be effective in terms of reducing 
anxiety symptoms, measured by the Halmilton Anxiety Rating Scale 
(HARS), which score was reduced by 44% at the end of the treatment 
period. It was also well tolerated and the patient only described 
transient side-effects such as dizziness, headache and sedation, which 
subsided 10 days [74].
Topiramate: Topiramate (TPM) is a sulfamate-substituted analog of 
fructose-1,6-diphosphate, whose efficacy in the treatment of SUD 
is thought to be through three mechanisms of action. Firstly, TPM 
facilitates Gamma-Aminobutyric Acid (GABA) transmission by 
binding to a non-BZD site on GABA-A receptors [75] and 
inhibits glutamatergic transmission at ionotropic Alpha-amino-3-hy-
droxi-5-Methilisoxazole-Propionic Acid (AMPA) and kainite 
glutamate receptors [76], which mediate voltage-dependent 
sodium [77] and L-type calcium currents [78]. Secondarily to these 
actions, TPM neuro-stabilizes and downstream reduces DA release in 
the corticomesolimbic system, which is involved in the mechanism 
of reward and reinforcement. In addition, TPM’s blockade of 
AMPA-type GLU receptors in the nucleus paragigantocellularis 
appears to inhibit noradrenergic neuron in the locus coeruleus, the 
activation of which plays an essential role in producing autonomic 
symptoms of withdrawal states. Finally, because of its weak 
inhibition of carbonic anhydrase, it could contribute to an 
anticonvulsant effect, a potentially important property in the 
treatment of withdrawal syndromes [79]. It has a specific pharma-
cokinetic profile, which is characterized by: 1) a biovariability of at 
least 80%; 2) it reaches its maximum concentration between 1.3-1.7 
hours post-ingestion; 3) it has a half-life of 19-23 hours; 4) it reaches 
steady-state plasma concentration in about 4 days; 5) it has low 
binding potential to proteins; 6) less than 20% of it undergoes 
metabolism to inactive metabolites; 7) up to 80% unchanged excretion 
in the urine; and 9) has little drug-to-drug interactions [32].
 Until now, there only exist two published case reports of TPM 
in the treatment of BD and BWS in the scientific literature. In 2003, 
Cheseaux et al., [80] described the case of a 41 year-old man with a 
very severe BD, who had been also using cannabis since the age of 13, 
and opiates and cocaine since the age of 20. He reported an intranasal 
consumption of 90 mg/day of Midazolam (MID), which had lasted for 
approximately 7 years. He was rapidly detoxified using TPM, starting 
with 300 mg on day 1, followed by 500 mg on days 2-3, with a taper 
out until day 9. The patient completed a successful BZD withdrawal, 
only describing insomnia and nausea as withdrawal symptoms. In 
addition, during the 2 subsequent months after being discharged from 
the inpatient program, he remained BZD-free [80]. More recently, 
Michopoulos et al., [81] have reported the case of a 44 year old woman 
who was diagnosed with Recurrent Major Depressive Disorder, 
Subthreshold Anxiety Disorder and histrionic traits, and a 
co-occurring ALP dependence, using 5-6 mg/day of ALP for 7 years, 
with multiple failed trials of long-acting BZDs, lamotrigine and 
Serotonin Selective Reuptake Inhibitors (SSRI). The patient was able 
to reduce ALP use to 1.5 mg/day at 6 months without experiencing 
withdrawal symptoms, while treated with TPM, following a tapering 
method which consisted in adding 25 mg/day of TPM, reaching a 
dosage of 200 mg/day, while ALP was simultaneously reduced by 
0.5 mg/day every 10 days [81].
Discussion
 Although multiple pharmacological agents have been investigated 
as adjunctive treatments for BWS and BD, there is only enough 
evidence for a few of them as to be considered efficacious for 
discontinuing log-term BZD use. One of these successful groups has 
been the one constituted by the AC agents.
 There are several potential advantages when using AC in the 
treatment of BD and BWS: 1) they reduce the likelihood of 
experiencing a seizure, symptom that is considered as a severe 
complication of BWS [33]; 2) they are effective in blocking the 
“kindling” effect, which refers to the progressive worsening of 
subsequent withdrawal episodes due to neural sensitization [34]; 3) 
they are absent of abuse liability and dependence [35]; 4) they are 
efficacious in treating anxiety and affective symptoms that can 
accompany protracted BWS [36]; and 5) they lack cognitive and 
psychomotor impairing effects [37,70].
 In regard to classical AC, on one hand, CBZ has been considered 
the only effective intervention together with gradual rather than 
abrupt withdrawal of BZD in a systematic Cochrane Database review 
[47]. Although it showed modest benefits in reducing withdrawal 
severity, it did significantly improve drug-free outcome. CBZ was 
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CR 2 months follow-up
ALP dependence (12-15 mg/d for 7 years) GBP (600 
mg/d) + Switch and tapering of CZP (2 mg/twice per 
day)
BZD discontinuation and reduction of 
withdrawal symptoms
GBP was effective in BZD discontinuation, with de-
crease of withdrawal symptoms The patient remained 
abstinent from BZD at 2 months follow-up
Zueco et al., 
N=17
OL 3 months Patients in OSP with MET
GBP (1200-4800 mg/d) + BZD tapering
Achievement of BZD-free
Withdrawal (WSRS) and anxiety (HARS) 
symptoms, perceived stress (PSS) and 
clinical impression (CGI)
60% of the patients remained BZD-free GBP was 
associated with reduction in withdrawal and anxiety 
symptoms, as well as perceived stress, and improve-





CS 12 days; 4 weeks follow-up
OXC (150-1200 mg/d) + Switching to equivalent-dos-
age of DZP and tapering 5 mg/2 d (LDD) and 25%/ 
2 d (HDD)
BZD withdrawal (CIWA)
OXC was associated with a successful withdrawal with-
out withdrawal symptoms Patients remained abstinent 




11-21 days; 6-months follow-up
OXC (150-1200 mg/d) + Switching to equivalent-dos-
age of DZP and tapering 5 mg/2 d (LDD) and 25%/ 
2 d (HDD)
BZD withdrawal (CIWA)
OXC was associated with a successful withdrawal 
without withdrawal symptoms
Patients remained abstinent from BZD 4 weeks after 
discharge
PREGABALIN
Bierman et al., 
N=1
CR
ALP dependence (4 years using 5 mg/die)
ALP was replaced with DZP 20 mg/d which was 
tapered until cessation and PGN was given up to 300 
mg/d
Effectiveness in the treatment of GAD
Effectiveness in improving diminished 
sleep quality due to BD and depression
PGN was effective for discontinuing BZD use, reducing 
withdrawal symptoms and improving sleep quality. 
When PGN was interrupted there were a rebound of 
BZD withdrawal symptoms
Oulis et al., 
N=4
CS
3-7 weeks PGN 225-600 mg/d during Anxiety levels (HARS) PGN reduced HARS scores by over 50%








PGN was effective for BZD discontinuation, decreasing 
HARS and HDRS scores by 53.2 (p=0.001) and 51.5% 
(p=0.001), respectively, and increasing MMSE score by 
9.4% (p=0.002)
Rubio et al., 
N=282
P, MC, O
12-weeks follow up period
PGN (25-450 mg/d) + BZD tapering 25% per week 
until complete withdrawn after 4 weeks
Primary outcome: Achievement of BZD-
free status at week 12
Sleep quality (MOS Sleep Scale)
Secondary outcomes: Withdrawal symp-
toms (BWSQ), anxiety (HARS) symptoms 
and patient’s functioning (CGI, SDS)
52% of patients treated with PGN were BZD-free at the 
end of the study
PGN was associated with improvements in anxiety 
(p<0.0001) and withdrawal (p<0.0001) symptoms, as 
well as global functioning (p<0.001)
Significant and clinically relevant improvement in sleep 
outcomes(p<0.001)
Rubio et al., 
N=282
Bobes et al., 
N=282




Stabilization period of 2-4 weeks with ALP (1-4 mg/d) 
+ PGN (300-600 mg/d) vs PLA + gradual BZD taper at 
a rate of 25% per week
Primary outcome: BZD-free achievement
Secondary outcomes:
Anxiety (HARS) and withdrawal (PWC) 
symptoms, and cognitive and psychomo-
tor functioning (DSST)
A non-significant higher proportion of patients remained 
BZD-free receiving PGN compared to PLA (51.4% 
vs 37.0%). Treatment with PGN was associated with 
significantly greater reductions in anxiety (p<0.001) and 
withdrawal (p=0.012) symptoms, and improvement in 
cognitive and psychomotor functioning
Oulis et al., 
N=14
NA
3-7 weeks, 2 months follow-up
BRO, ALP and LZM dependence
PGN (150-900 mg/d) + BZD tapering
Global cognitive functioning (MMEE)
Specific neuropsychological assessment 
(CANTAB)
PGN was associated with an improvement in overall 
cognitive functioning (p=0.017), which was attributable 
mainly to their improvement in orientation (p<0.03) 
and to a much lesser extent to an improvement in 
memory recall (p N.S.). PGN was also associated with 
an improvement in measures of psychomotor speed 
(p=0.041), visuospatial memory (p=0.02) and learning 
(p=0.011)
TIAGABINE
Oulis et al., 
N=1
CR
1 week, 4 weeks follow-up
Elderly patient
BRO dependence (75 mg/day)
TGB (up to 15 mg/d) + BRO tapering by 10 mg/d 
within 1 week
Reduction of anxiety symptoms (HARS)
TGB was found to be effective in terms of reduction of 
anxiety symptoms. HARS score was reduced by 44% 





9 days, 2 months follow-up
MID dependence (90 mg/d)
TPM (300-500 mg/day) + BZD tapering
Efficacy in BZD withdrawal
TPM was useful for BZD detoxification (only insomnia 
and nausea were reported)




10 days, 6 months follow-up
ALP dependence (5-6 mg/d)
TPM was given in a dose of 25 mg/d reaching 200 
mg/d + ALP tapering by 0,5 mg/d
Efficacy in BZD withdrawal
TPM treatment was associated with a reduction in 
ALP use to 1.5 mg/d at 6 months without withdrawal 
symptoms
Table 2: Studies in which new AC have been assessed for the discontinuation of long-term BZD-use.
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considered to be effective particularly in patients receiving BZDs at 20 
mg/day or more DZP-equivalent dosages. These findings are partially 
supported by the results of a meta-analysis which included 29 
articles and in which augmentation with CBZ as a BZD 
discontinuation strategy was considered as successful, although the 
effect of CBZ only showed a trend towards statistical significance 
(p=0.06) [9]. On the other hand, in spite of initial cases report 
showing promising results in regard with the use of VPA in the 
treatment of BD and BWS, the only randomized, double-blind, 
placebo-controlled trial conducted to date, failed to demonstrate 
its efficacy in reducing the severity of BZD withdrawal symptoms, 
and only succeed in terms of achievement rates of BZD-free at the 
endpoint of the study [17].
 Nevertheless, CBZ and VPA’s use is frequently avoided in the 
clinical practice because they are susceptible to cause enzymatic 
induction (CBZ) or inhibition (VPA), resulting in drug-to-drug 
interactions with a decrease or increase, respectively, in the serum 
concentrations of other drugs, which requires careful monitoring. In 
addition, they are associated with hepatic and hematologic toxicity, 
and undesirable side effects such as dizziness, diplopia, ataxia, allergic 
skin reactions, pruritus, vomits and nausea, as well as changes in 
the electrolytes, especially hyponatremia, in the case of CBZ, and 
gastrointestinal disturbances, confusion, tremor, hepatic or central 
encephalopathy and pancreatitis in the case of VPA [31,82,83]. Newer 
AC offer the advantage of having a rapid onset of action, lower 
toxicity, fewer side effects, and lower interaction with alcohol and 
other drugs [32].
 Current available data only supports the use of the new AC PGN 
in the treatment of BD and BWS. Two robust studies, a 12-week, 
prospective, observational, multicenter study including 282 patients 
[36,68], and a 12-week, randomized, double-blind, placebo-controlled 
trial including 106 patients [70], have found that PGN is effective 
in reducing withdrawal and anxiety symptoms, as well as sleep 
parameters, cognitive and psychomotor functioning, and to a 
lesser extent it helps in achieving the maintenance of BZD abstinence. 
According to the studies reviewed, PGN’s required dosage range in 
BD seems to be much higher (by more than 70%) than in AUD. PGN 
might exert its therapeutic action through the reduction of anxiety 
symptoms [36,70]. Although potential tolerance and abuse has been 
described associated to PGN treatment, PGN’s potential for physical 
and psychological dependence is much lower than that of BZDs [66]. 
PGN’s most frequent, though mostly transient and dose-related, side 
effects are dizziness, somnolence, blurred vision, dry mouth, weight 
gain, peripheral edema and attention and concentration disturbances 
[66].
 Although GBP and TPM, have been found to be effective for the 
treatment of AUD [32,82-84], only anecdotal cases report and small 
studies have been published to date in regard to their use in BD and 
BWS [55,56,80,81], and further studies are needed to consider them 
as pharmacological agents for discontinuing long-term BZD-use. In 
addition, specifically in the case of TPM, its side effects, especially 
those related to paresthesias, anorexia and difficulty with memory 
and concentration may limit its widespread use [32]. The same 
happens with OXC and TGB, agents that although they have 
demonstrated their efficacy in treating different anxiety disorders and 
SUD [72,85,86], have not enough evidence for the treatment of BD 
and BWS [58,59,74].
 To sum up, to date, among AC agents, only CBZ and PGN can 
be considered as augmentation alternatives for the treatment of 
long-term BZD use. Whereas CBZ has shown to be more effective 
in terms of BZD-free outcomes, PGN exerts its beneficial action by 
reducing withdrawal and anxiety symptoms. Further randomized, 
double-blind, placebo-controlled studies are necessary before 
considering other AC agents as effective pharmacotherapies for 
reducing BZD withdrawal severity and achieving long-term BZD 
abstinence at follow-up.
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